

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



NEUSOFT XIKANG HOLDINGS INC.

東軟熙康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9686)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces the following changes in the composition of the Board and its certain committees that with effect from 18 December 2023: (1) Dr. FANG Weiyi has resigned as an independent non-executive Director and from his respective positions in the committees of the Board; (2) Dr. QI Guoxian has been appointed as an independent non-executive Director, a member of the Remuneration Committee, a member of the Nomination Committee and a member of the Strategy Committee.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of NEUSOFT XIKANG HOLDINGS INC. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces that Dr. FANG Weiyi (“**Dr. FANG**”) has resigned, with effect from 18 December 2023, as an independent non-executive Director, a member of the remuneration committee (the “**Remuneration Committee**”), a member of the nomination committee (the “**Nomination Committee**”) and a member of the strategy committee (the “**Strategy Committee**”) of the Company due to his personal work arrangements. Dr. FANG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his resignation which needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Dr. FANG for his valuable efforts and contributions to the Group during his tenure of office as Director.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce the following appointment: Dr. QI Guoxian (“**Dr. QI**”) has been appointed as an independent non-executive Director, a member of the Remuneration Committee, a member of the Nomination Committee and a member of the Strategy Committee, with effect from 18 December 2023.

The details of the newly appointed Director are as follows:

Dr. QI, aged 68, is an independent non-executive Director of the Company from 18 December 2023.

Dr. QI served as the cardiologist, professor and department director in the First Hospital of China Medical University from December 1982 to September 2010. From September 2010 to September 2017, he served as the professor and department director of the Department of Geriatrics of the First Hospital of China Medical University. He has served as the professor and chief physician of the Department of Geriatrics of the First Hospital of China Medical University since September 2017.

Dr. QI has also held a number of academic positions in the medical field. He has served as a member of the Standing Committee of the Geriatrics Branch of the Chinese Medical Association since 2009. Since 2019, he has served as the chairman of the Geriatric Disease Prevention and Treatment Professional Committee of the Preventive Medicine Association of Liaoning Province. And since 2023, he has served as the president of the Liaoning Provincial Geriatrics Society.

Dr. QI has won several awards in the medical field. He was awarded the May 1st Labor Medal of Liaoning Province from Liaoning Federation of Trade Union in 2014 and the first Liaoning famous doctor from Health Commission of Liaoning Province in 2015.

Dr. QI obtained a bachelor’s degree in medicine from China Medical University in June 1982 and a master’s degree in internal medicine from the First Hospital of China Medical University in June 1987. He obtained his doctorate degree from the Department of Cardiology of the First Hospital of China Medical University in June 2000. In December 2000, Dr. QI was awarded the titles of professor and chief physician by the Liaoning Provincial Department of Human Resources and Social Security, and was awarded the title of doctoral supervisor by China Medical University in the same year.

Dr. QI has entered into a letter of appointment with the Company for a term of three years commencing from 18 December 2023, which can be terminated by either party by giving to the other party not less than one month's notice in writing. According to the letter of appointment, the annual Director's fee of Dr. QI as an independent non-executive Director payable by the Company is HK\$150,000. Dr. QI's remuneration was determined by the Board with reference to the recommendation made by the Remuneration Committee after taking into account market conditions and his duties and responsibilities with the Group.

Pursuant to the articles of association of the Company, Dr. QI will hold office as an independent non-executive Director until the next annual general meeting of the Company and will be subject to retirement by rotation and re-election at that meeting.

As at the date of this announcement, Dr. QI does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, Dr. QI (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling Shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") of the Company; and (iv) does not have any other major appointments or professional qualifications. Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Dr. QI that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Dr. QI for his new appointment.

By order of the Board of
NEUSOFT XIKANG HOLDINGS INC.
Dr. LIU Jiren
Chairman and non-executive Director

PRC, 18 December 2023

As at the date of this announcement, the Board comprises Ms. ZONG Wenhong as the executive Director; Dr. LIU Jiren, Ms. LU Zhaoxia, Dr. WANG Nan, Mr. PU Chengchuan and Dr. CHEN Lianyong as the non-executive Directors; and Dr. CHEN Yan, Dr. QI Guoxian and Dr. YIN Guisheng as the independent non-executive Directors.